DK1179067T3 - Neurobeskyttende egenskaber hos GDF-15, et medlem af TGF-beta-superfamilien - Google Patents
Neurobeskyttende egenskaber hos GDF-15, et medlem af TGF-beta-superfamilienInfo
- Publication number
- DK1179067T3 DK1179067T3 DK00935043T DK00935043T DK1179067T3 DK 1179067 T3 DK1179067 T3 DK 1179067T3 DK 00935043 T DK00935043 T DK 00935043T DK 00935043 T DK00935043 T DK 00935043T DK 1179067 T3 DK1179067 T3 DK 1179067T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- nucleic acids
- tgf
- vector
- gdf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Eye Examination Apparatus (AREA)
- Developing Agents For Electrophotography (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- External Artificial Organs (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99109714 | 1999-05-17 | ||
EP99114853 | 1999-07-29 | ||
PCT/EP2000/004445 WO2000070051A1 (fr) | 1999-05-17 | 2000-05-16 | PROPRIETES NEUROPROTECTRICES DU GDF-15, UN NOUVEAU MEMBRE DE LA SUPERFAMILLE DE TGF-$g(b) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1179067T3 true DK1179067T3 (da) | 2007-03-19 |
Family
ID=26153004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00935043T DK1179067T3 (da) | 1999-05-17 | 2000-05-16 | Neurobeskyttende egenskaber hos GDF-15, et medlem af TGF-beta-superfamilien |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060148709A1 (fr) |
EP (1) | EP1179067B1 (fr) |
JP (1) | JP2002543841A (fr) |
AT (1) | ATE348164T1 (fr) |
AU (1) | AU5067100A (fr) |
CA (1) | CA2372119A1 (fr) |
CY (1) | CY1105910T1 (fr) |
DE (1) | DE60032355T2 (fr) |
DK (1) | DK1179067T3 (fr) |
ES (1) | ES2275513T3 (fr) |
PT (1) | PT1179067E (fr) |
WO (1) | WO2000070051A1 (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE470863T1 (de) * | 2000-04-20 | 2010-06-15 | St Vincents Hosp Sydney | Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1) |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
CA2660691C (fr) * | 2006-08-04 | 2020-01-14 | Medizinische Hochschule Hannover | Moyens et procedes d'evaluation du risque d'interventions cardiaques a partir du gene gdf-15 |
EP1884777A1 (fr) * | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Moyens et procédés d'évaluation du risque d'interventions cardiaques basées sur GDF-15 |
CN100588717C (zh) * | 2007-03-21 | 2010-02-10 | 中国医学科学院阜外心血管病医院 | 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途 |
JP2011501112A (ja) | 2007-10-10 | 2011-01-06 | エフ.ホフマン−ラ ロシュ アーゲー | 心筋梗塞のモニタリング及びその治療のための手段及び方法 |
EP2103943A1 (fr) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 pour évaluer un risque cardiovasculaire en respectant l'administration des médicaments anti-inflammatoires |
US20120107420A1 (en) | 2008-10-31 | 2012-05-03 | St Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
KR20100054711A (ko) * | 2008-11-14 | 2010-05-25 | 메디포스트(주) | 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물 |
EP2211182A1 (fr) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Procédé pour l'évaluation de la gravité de la cirrhose du foie |
EP2209003A1 (fr) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Moyens et procédés pour différencier la fibrose de la cirrhose |
RU2548710C2 (ru) | 2009-09-17 | 2015-04-20 | Ф.Хоффманн-Ля Рош Аг | Мультимаркерная панель для гипертрофии левого желудочка |
EP2336784B1 (fr) | 2009-12-18 | 2017-08-16 | Roche Diagnostics GmbH | GDF-15 et/ou troponine T pour prédire l'insuffisance rénale chez des patients opérés du c'ur |
WO2011102461A1 (fr) * | 2010-02-22 | 2011-08-25 | 公立大学法人横浜市立大学 | Protéine exprimée spécifiquement dans l'adénocarcinome de l'ovaire à cellules claires et ses applications d'utilisation |
EP2388594A1 (fr) | 2010-05-17 | 2011-11-23 | Roche Diagnostics GmbH | Moyens et procédés basés sur GDF-15 pour la prédiction de la survie et de la guérison dans une inflammation aiguë |
WO2012020045A1 (fr) | 2010-08-10 | 2012-02-16 | Roche Diagnostics Gmbh | Procédé de sélection de patients atteints d'une maladie des artères coronaires stabilisée en vue d'une icp ou d'un traitement médical |
CN103080746B (zh) | 2010-08-26 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
EP2439535A1 (fr) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnostic de maladies cardiaques liées au diabète et GDF-15 et troponine en tant que prédicteurs pour le développement du diabète sucré de type 2 |
WO2012066140A1 (fr) | 2010-11-19 | 2012-05-24 | Roche Diagnostics Gmbh | Procédé de surveillance de l'entraînement physique chez des individus sains et malades |
EP2490027A1 (fr) | 2011-02-15 | 2012-08-22 | Roche Diagnostics GmbH | Moyens et procédés pour le diagnostic de complications de la grossesse basés sur GDF-15 et PlGF/sFlt1 |
WO2012146645A1 (fr) | 2011-04-27 | 2012-11-01 | Roche Diagnostics Gmbh | Diagnostic de blessure du rein suite à une intervention chirurgicale |
EP2574932A1 (fr) | 2011-09-30 | 2013-04-03 | Roche Diagnostics GmbH | sFlt1 chez des sujets pendant ou tout de suite après un exercice physique |
EP2581040A1 (fr) | 2011-10-10 | 2013-04-17 | Roche Diagnostics GmbH | Entraînement physiologique associé au risque de l'hypertrophie cardiaque basée sur le TnT et guide chez les athlètes |
ES2595028T3 (es) | 2011-10-17 | 2016-12-27 | F. Hoffmann-La Roche Ag | Diagnóstico basado en Troponina y BNP de pacientes en riesgo y causa de ictus |
EP2830646B1 (fr) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions et méthodes d'utilisation pour le traitement de troubles métaboliques |
EP2597467A1 (fr) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Supports et procédés pour diagnostic proSP-B des congestions pulmonaires chez les patients souffrant de syndromes coronaires aigus |
ES2742287T3 (es) | 2012-09-26 | 2020-02-13 | Univ Wuerzburg J Maximilians | Anticuerpos monoclonales contra el factor de diferenciación de crecimiento 15 (GDF-15) |
CN104838271B (zh) | 2012-12-04 | 2018-07-03 | 霍夫曼-拉罗奇有限公司 | 心力衰竭疗法的选择中的生物标记物 |
CA2896076C (fr) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anticorps anti-gdf15 |
WO2014120619A2 (fr) | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions et procédés à utiliser pour le traitement de troubles métaboliques |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
EP2843414B1 (fr) | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marqueur pour la stratification de traitement de statine dans l'insuffisance cardiaque |
US10274502B2 (en) | 2013-11-04 | 2019-04-30 | The Regents Of The University Of Michigan | Biomarkers and methods for progression prediction for chronic kidney disease |
EP3470848A3 (fr) | 2014-01-28 | 2019-05-22 | Roche Diagnostics GmbH | Biomarqueurs pour l'évaluation de risques et la surveillance thérapeutique chez des patients atteints d'insuffisance cardiaque guidée par des peptides natriurétiques |
PT3653644T (pt) | 2014-03-26 | 2023-12-19 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro |
ES2676553T3 (es) | 2014-03-26 | 2018-07-20 | F. Hoffmann-La Roche Ag | IGFBP7 para el diagnóstico de la disfunción diastólica |
CN106573966B (zh) | 2014-07-30 | 2022-03-01 | Ngm生物制药有限公司 | 用于治疗代谢异常的组合物和方法 |
ES2708325T5 (es) | 2014-10-29 | 2023-02-17 | Hoffmann La Roche | Biomarcadores para la predicción del riesgo de progresión de insuficiencia cardiaca crónica y de la mortalidad |
MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
JP6858181B2 (ja) | 2015-10-02 | 2021-04-14 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのgdf−15 |
ES2937167T3 (es) | 2015-10-02 | 2023-03-24 | Univ Wuerzburg J Maximilians | Terapia de combinación que usa inhibidores de factor de crecimiento y diferenciación 15 (GDF-15) humano y bloqueadores del punto de control inmunitario |
KR102083104B1 (ko) | 2015-10-08 | 2020-02-28 | 에프. 호프만-라 로슈 아게 | 수술 전 측정시 aki 의 위험 예측을 위한 igfbp7 |
CN105603093A (zh) * | 2016-02-05 | 2016-05-25 | 广州复能基因有限公司 | 以MIC-1 cDNA为模板制备RNA探针的方法 |
TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
JP2021014434A (ja) * | 2019-07-12 | 2021-02-12 | 国立大学法人千葉大学 | うつ病またはうつ症状の予防または治療剤としてのトランスフォーミング増殖因子β1 |
EP3943946A1 (fr) | 2020-07-20 | 2022-01-26 | F. Hoffmann-La Roche AG | Gdf-15 pour prédire la gravité de la maladie d'un patient atteint de covid-19 |
CN117321419A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的Presepsin标志物组 |
JP2024515086A (ja) | 2021-04-30 | 2024-04-04 | エフ. ホフマン-ラ ロシュ アーゲー | 敗血症の早期検出のためのgdf15マーカーパネル |
WO2023052446A1 (fr) | 2021-09-29 | 2023-04-06 | F. Hoffmann-La Roche Ag | Panels de marqueurs mr-proadm pour la détection précoce de la septicémie |
WO2023156655A1 (fr) | 2022-02-21 | 2023-08-24 | F. Hoffmann-La Roche Ag | Panels de marqueurs ddl1 pour la détection précoce d'une septicémie |
WO2023175176A1 (fr) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Combinaisons de marqueurs cmybpc pour discrimination précoce de l'infarctus du myocarde aigu de type 2 par rapport au type 1 |
WO2023175152A1 (fr) | 2022-03-18 | 2023-09-21 | Roche Diagnostics Gmbh | Combinaisons de marqueurs de troponine pour discrimination précoce de l'infarctus du myocarde aigu de type 2 par rapport au type 1 |
CN114891086B (zh) * | 2022-06-01 | 2024-03-26 | 恺佧生物科技(上海)有限公司 | 一种生物素标记的gdf15的复性方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180602B1 (en) * | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
US5994102A (en) * | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
ATE423788T1 (de) * | 1995-06-22 | 2009-03-15 | St Vincents Hosp Sydney | Neues tgf-beta-ahnliches cytokin |
US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US6524802B1 (en) * | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
KR20000038040A (ko) * | 1996-09-11 | 2000-07-05 | 오르토-맥네일 파마슈티칼 인코퍼레이티드 | 전립선 암을 치료하기 위한 tnf-베타-형 단백질, 및 관련 핵산 분자, 약제학적 조성물 및 방법 |
FR2761258B1 (fr) * | 1997-03-26 | 1999-06-11 | Rhone Poulenc Rorer Sa | Procede de stimulation de la regeneration nerveuse |
DE69821629T2 (de) * | 1997-09-19 | 2005-01-13 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Kombinationen von Cytokinen mit neurotroper Aktivität |
EP1176870B1 (fr) * | 1999-04-26 | 2007-06-13 | Applied Protein Sciences, LLC | Polypeptides tgf-alpha fragments fonctionnels et leurs procedes d'utilisation |
-
2000
- 2000-05-16 CA CA002372119A patent/CA2372119A1/fr not_active Abandoned
- 2000-05-16 EP EP00935043A patent/EP1179067B1/fr not_active Expired - Lifetime
- 2000-05-16 PT PT00935043T patent/PT1179067E/pt unknown
- 2000-05-16 AU AU50671/00A patent/AU5067100A/en not_active Abandoned
- 2000-05-16 DK DK00935043T patent/DK1179067T3/da active
- 2000-05-16 ES ES00935043T patent/ES2275513T3/es not_active Expired - Lifetime
- 2000-05-16 JP JP2000618457A patent/JP2002543841A/ja active Pending
- 2000-05-16 WO PCT/EP2000/004445 patent/WO2000070051A1/fr active IP Right Grant
- 2000-05-16 AT AT00935043T patent/ATE348164T1/de not_active IP Right Cessation
- 2000-05-16 DE DE60032355T patent/DE60032355T2/de not_active Expired - Fee Related
-
2006
- 2006-03-09 US US11/372,281 patent/US20060148709A1/en not_active Abandoned
-
2007
- 2007-01-08 CY CY20071100023T patent/CY1105910T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1105910T1 (el) | 2011-02-02 |
US20060148709A1 (en) | 2006-07-06 |
ES2275513T3 (es) | 2007-06-16 |
WO2000070051A1 (fr) | 2000-11-23 |
EP1179067B1 (fr) | 2006-12-13 |
PT1179067E (pt) | 2007-01-31 |
AU5067100A (en) | 2000-12-05 |
JP2002543841A (ja) | 2002-12-24 |
EP1179067A1 (fr) | 2002-02-13 |
DE60032355D1 (de) | 2007-01-25 |
ATE348164T1 (de) | 2007-01-15 |
CA2372119A1 (fr) | 2000-11-23 |
DE60032355T2 (de) | 2007-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1179067T3 (da) | Neurobeskyttende egenskaber hos GDF-15, et medlem af TGF-beta-superfamilien | |
BRPI0616712B8 (pt) | método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas | |
DK1144607T3 (da) | Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger | |
ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
WO2005111066A8 (fr) | Polypeptides issus d'haemophilus influenzae non typable | |
ATE180261T1 (de) | Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen | |
AU4829999A (en) | Methods for rapidly identifying small organic ligands | |
BRPI0513135A (pt) | bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo | |
WO2004033631A8 (fr) | Sequences d'acides nucleiques et polypeptidiques de lawsonia intracellularis et methodes d'utilisation | |
DE60140773D1 (de) | Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS) | |
WO2002002627A3 (fr) | Proteine zcyto21de type interferon | |
ATE380867T1 (de) | Lactoferrinrezeptorgen von moraxella | |
ATE440860T1 (de) | An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen | |
WO2020198264A8 (fr) | Clivages modifiés, utilisations et kits correspondants | |
DE69618614T2 (de) | NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG | |
FR2660757B1 (fr) | Procede d'identification ou de dosage de proteines et applications. | |
DE60034117D1 (de) | Verfahren zur herstelllung von gonadotropin-zusammensetzungen | |
WO2002074956A3 (fr) | Facteurs promoteurs de la survie des neurones dopaminergiques et utilisations associes | |
Pedrotti et al. | Purified native microtubule associated protein MAP1A: kinetics of microtubule assembly and MAP1A/tubulin stoichiometry | |
EP1702985A3 (fr) | Ségments préférés de la neural thread protein et méthodes utilisant ceux-ci | |
WO2001029220A3 (fr) | Peptides antigeniques mage-a12 et utilisation | |
ATE187202T1 (de) | Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung | |
WO2003042374A3 (fr) | Isolement de neurones et de cellules souches pour fibres nerveuses a partir d'un echantillon | |
DE50013400D1 (de) | Dna-sequenz und rekombinante herstellung eines graminaen-allergens | |
DE69631624D1 (de) | Antikörper gegen menschliches restrictin |